Review ArticleSystematic Review
Open Access

Erlotinib for advanced hepatocellular carcinoma

A systematic review of phase II/III clinical trials

Jing Zhang, Yuan Zong, Gang-Zhu Xu and Ke Xing
Saudi Medical Journal November 2016, 37 (11) 1184-1190; DOI: https://doi.org/10.15537/smj.2016.11.16267

References

  1. ↵
    1. International Agency for Research on Cancer, World Health Organization
    GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012, Available from: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. Accessed 2016 August 18.
  2. ↵
    1. El-Serag HB
    (2012) Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142:1264–1273.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Kim DY,
    2. Han KH
    (2012) Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer 1:2–14.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Cheng JW,
    2. Lv Y
    (2013) New progress of non-surgical treatments for hepatocellular carcinoma. Med Oncol 30:381.
    OpenUrl
  5. ↵
    1. Van den Eynde M,
    2. Baurain JF,
    3. Mazzeo F,
    4. Machiels JP
    (2011) Epidermal growth factor receptor targeted therapies for solid tumours. Acta Clin Belg 66:10–17.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Hirte HW
    (2013) Profile of erlotinib and its potential in the treatment of advanced ovarian carcinoma. Onco Targets Ther 6:427–435.
    OpenUrl
  7. ↵
    1. Philip PA,
    2. Mahoney MR,
    3. Allmer C,
    4. Thomas J,
    5. Pitot HC,
    6. Kim G,
    7. et al.
    (2005) Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 23:6657–6663.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Thomas MB,
    2. Chadha R,
    3. Glover K,
    4. Wang X,
    5. Morris J,
    6. Brown T,
    7. et al.
    (2007) Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 110:1059–1067.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Thomas MB,
    2. Morris JS,
    3. Chadha R,
    4. Iwasaki M,
    5. Kaur H,
    6. Lin E,
    7. et al.
    (2009) Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 27:843–850.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Kaseb AO,
    2. Garrett-Mayer E,
    3. Morris JS,
    4. Xiao L,
    5. Lin E,
    6. Onicescu G,
    7. et al.
    (2012) Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial. Oncology 82:67–74.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Philip PA,
    2. Mahoney MR,
    3. Holen KD,
    4. Northfelt DW,
    5. Pitot HC,
    6. Picus J,
    7. et al.
    (2012) Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer. Cancer 118:2424–2430.
    OpenUrl
  12. ↵
    1. Yau T,
    2. Wong H,
    3. Chan P,
    4. Yao TJ,
    5. Pang R,
    6. Cheung TT,
    7. et al.
    (2012) Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease. Invest New Drugs 30:2384–2390.
    OpenUrlPubMed
  13. ↵
    1. Govindarajan R,
    2. Siegel E,
    3. Makhoul I,
    4. Williamson S
    (2013) Bevacizumab and erlotinib in previously untreated inoperable and metastatic hepatocellular carcinoma. Am J Clin Oncol 36:254–257.
    OpenUrlPubMed
  14. ↵
    1. Hsu CH,
    2. Kang YK,
    3. Yang TS,
    4. Shun CT,
    5. Shao YY,
    6. Su WC,
    7. et al.
    (2013) Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: a multicenter phase II study. Oncology 85:44–52.
    OpenUrlPubMed
  15. ↵
    1. Chiorean EG,
    2. Ramasubbaiah R,
    3. Yu M,
    4. Picus J,
    5. Bufill JA,
    6. Tong Y,
    7. et al.
    (2012) Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101. Oncologist 17:13.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Zhu AX,
    2. Rosmorduc O,
    3. Evans TR,
    4. Ross PJ,
    5. Santoro A,
    6. Carrilho FJ,
    7. et al.
    (2015) SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 33:559–566.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Fang P,
    2. Hu JH,
    3. Cheng ZG,
    4. Liu ZF,
    5. Wang JL,
    6. Jiao SC
    (2012) Efficacy and safety of bevacizumab for the treatment of advanced hepatocellular carcinoma: a systematic review of phase II trials. PLoS One, 7e49717.
  18. ↵
    1. Llovet JM,
    2. Ricci S,
    3. Mazzaferro V,
    4. Hilgard P,
    5. Gane E,
    6. Blanc JF,
    7. et al.
    (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390.
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    1. Cheng AL,
    2. Kang YK,
    3. Chen Z,
    4. Tsao CJ,
    5. Qin S,
    6. Kim JS,
    7. et al.
    (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34.
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    1. Gauthier A,
    2. Ho M
    (2013) Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update. Hepatol Res 43:147–154.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Zhao Y,
    2. Adjei AA
    (2015) Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor. Oncologist 20:660–673.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Duran I,
    2. Hotté SJ,
    3. Hirte H,
    4. Chen EX,
    5. MacLean M,
    6. Turner S,
    7. et al.
    (2007) Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. Clin Cancer Res 13:4849–4857.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Sieghart W,
    2. Pinter M,
    3. Dauser B,
    4. Rohr-Udilova N,
    5. Piguet AC,
    6. Prager G,
    7. et al.
    (2012) Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma. J Hepatol 57:592–599.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Llovet JM,
    2. Peña CE,
    3. Lathia CD,
    4. Shan M,
    5. Meinhardt G,
    6. Bruix J,
    7. et al.
    (2012) Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 18:2290–2300.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Stasi I,
    2. Cappuzzo F
    (2014) Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer. Transl Respir Med 2:2.
    OpenUrl
  26. ↵
    1. Yeatts SD
    (2013) Novel methodologic approaches to phase I, II, and III trials. Stroke 44(6 Suppl 1):S116–S118.
    OpenUrlFREE Full Text
  27. ↵
    1. Shao YY,
    2. Hsu CH,
    3. Cheng AL
    (2015) Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there? World J Gastroenterol 21:10336–10347.
    OpenUrl
  28. ↵
    1. Saad ED,
    2. Katz A
    (2009) Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined. Ann Oncol 20:460–464.
    OpenUrlCrossRefPubMedWeb of Science
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section